Navigation Links
NeurogesX Opens Investigational New Drug Application for Capsaicin Liquid Formulation NGX-1998

SAN MATEO, Calif., June 3 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced that it submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration for the clinical development of NGX-1998, the Company's product candidate utilizing a high-concentration liquid formulation of capsaicin. The Company further announced that the IND is now effective and that it may commence clinical studies under this IND.

Anthony DiTonno, President and CEO, commented, "The opening of the IND for NGX-1998 is an important milestone for NeurogesX as it allows us to commence the clinical development of the high-concentration liquid capsaicin formulation. NGX-1998 contains the same active ingredient as our lead product candidate, NGX-4010, but its proprietary liquid formulation is designed to enable rapid delivery of capsaicin into the skin. In doing so, we believe that NGX-1998 offers the potential for short treatment times and the potential for expanding the addressable market of our capsaicin based product candidate pipeline."

NGX-1998 was previously studied in two Phase I studies in healthy volunteers conducted under an exploratory IND. With the new IND in place, NeurogesX intends to initiate a Phase I clinical trial in 2008 to evaluate potential controls for studies in peripheral neuropathic pain.

About NeurogesX, Inc.

NeurogesX (NASDAQ: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company believes offers significant advantages over other pain therapies. NeurogesX' marketing authorization application (MAA) to the European Medicines Agency (EMEA) was accepted for review in September 2007 and NeurogesX plans to file a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) in 2008 for PHN.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the timing of the initiation of the Phase 1 clinical trial for NGX-1998; the potential expansion of addressable markets for NeurogesX' product candidates; and the expected benefits of NeurogesX' potential products, including its lead product candidate NGX-4010 and its liquid formulation product candidate NGX-1998. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, NeurogesX' product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010 or NGX-1998, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX-4010 or NGX-1998 and the advantages of NGX-4010 or NGX-1998 over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.


Stephen Ghiglieri

(650) 358-3310

The Ruth Group

Investors / Media

Stephanie Carrington / Jason Rando

(646) 536-7017 / 7025

SOURCE NeurogesX
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. NeurogesX Appoints New Director to the Board
3. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
4. NeurogesX Expands Senior Management Team
5. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
7. NeurogesX, Inc. Announces $25 Million Private Placement
8. NeurogesX Closes $25 Million Private Placement
9. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
10. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
11. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
(Date:11/24/2015)... 24, 2015  Twist Bioscience, a company focused ... Ph.D., Twist Bioscience chief executive officer, will present ... December 1, 2015 at 3:10 p.m. Eastern Time at The ... --> --> ... Bioscience is on Twitter. Sign up to follow ...
(Date:11/24/2015)... , Nov. 24, 2015 Capricor Therapeutics, ... focused on the discovery, development and commercialization of first-in-class ... Chief Executive Officer, is scheduled to present at the ... at 10:50 a.m. EST, at The Lotte New York ... . . --> ...
(Date:11/24/2015)... , Nov. 24, 2015 According to two new ... 2005. This is something that many doctors, scientists, and public ... questions remains: with fewer PSA tests being done, will there ... Dr. David Samadi, "Despite the efforts made ... remains the second leading cancer cause of death in men, ...
(Date:11/23/2015)... ... 23, 2015 , ... Noblis, Inc., a leading provider of science, technology, and ... Geospatial Intelligence Agency (NGA), has joined the Noblis NSP team as President of the ... intelligence community and the private sector,” said L. Roger Mason, Jr., Ph.D. , ...
Breaking Biology Technology:
(Date:11/18/2015)... -- As new scientific discoveries deepen our understanding of how ... face challenges in better using that knowledge to guide ... more children continue to survive pediatric cancer, that counseling ... John M. Maris, M.D ., a pediatric ... . --> John M. Maris, M.D ...
(Date:11/17/2015)... Calif. , Nov. 17, 2015  Vigilant Solutions ... has joined its Board of Directors. ... Board after recently retiring from the partnership at TPG ... 107 companies with over $140 Billion in revenue.  He ... improvement across all the TPG companies, from 1997 to ...
(Date:11/12/2015)... 12, 2015  Arxspan has entered into an ... Harvard for use of its ArxLab cloud-based suite ... The partnership will support the institute,s efforts to ... research information internally and with external collaborators. The ... managing the Institute,s electronic laboratory notebook, compound and ...
Breaking Biology News(10 mins):